Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study

NCT07488572 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma (RCC)
Metastatic Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Yivoximab

Sponsor

Sun Yat-sen University